Query author contributions in Reactome Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome .
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person CDK6 inhibitors bind CDK6
Class:Id Reaction:9754129 _displayName CDK6 inhibitors bind CDK6 _doRelease TRUE _timestamp 2022-02-08 21:28:22 authored [InstanceEdit:9754145] Orlic-Milacic, Marija, 2021-09-21 compartment [Compartment:7660] nucleoplasm created [InstanceEdit:9754131] Orlic-Milacic, Marija, 2021-09-21 edited [InstanceEdit:9758459] Orlic-Milacic, Marija, 2021-11-12 input [DefinedSet:9754132] CDK6 inhibitors [nucleoplasm] [DefinedSet:9756822] p-T177-CDK6:CCND [nucleoplasm] [Homo sapiens] isChimeric FALSE literatureReference [LiteratureReference:9754230] Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine [LiteratureReference:9754462] Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance [LiteratureReference:9754599] In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00 [LiteratureReference:9755161] CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest [LiteratureReference:9755171] Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models [LiteratureReference:9755986] Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors [LiteratureReference:9756000] Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression [LiteratureReference:9756010] Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer [LiteratureReference:9756219] Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells [LiteratureReference:9756209] Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition [LiteratureReference:9756229] Cyclin D type does not influence cell cycle response to DNA damage caused by ionizing radiation in multiple myeloma tumours [LiteratureReference:9756310] Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells [LiteratureReference:9756514] The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes [LiteratureReference:9756534] The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival [LiteratureReference:9756717] Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts [LiteratureReference:9756846] Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product modified [InstanceEdit:9754239] Orlic-Milacic, Marija, 2021-09-22 [InstanceEdit:9754469] Orlic-Milacic, Marija, 2021-09-27 [InstanceEdit:9754605] Orlic-Milacic, Marija, 2021-09-30 [InstanceEdit:9755183] Orlic-Milacic, Marija, 2021-10-06 [InstanceEdit:9755998] Orlic-Milacic, Marija, 2021-10-12 [InstanceEdit:9756005] Orlic-Milacic, Marija, 2021-10-12 [InstanceEdit:9756032] Orlic-Milacic, Marija, 2021-10-12 [InstanceEdit:9756221] Orlic-Milacic, Marija, 2021-10-12 [InstanceEdit:9756231] Orlic-Milacic, Marija, 2021-10-12 [InstanceEdit:9756315] Orlic-Milacic, Marija, 2021-10-13 [InstanceEdit:9756516] Orlic-Milacic, Marija, 2021-10-15 [InstanceEdit:9756545] Orlic-Milacic, Marija, 2021-10-15 [InstanceEdit:9756554] Orlic-Milacic, Marija, 2021-10-15 [InstanceEdit:9756719] Orlic-Milacic, Marija, 2021-10-17 [InstanceEdit:9756838] Orlic-Milacic, Marija, 2021-10-18 [InstanceEdit:9756854] Orlic-Milacic, Marija, 2021-10-19 [InstanceEdit:9757610] Orlic-Milacic, Marija, 2021-11-02 [InstanceEdit:9757978] Orlic-Milacic, Marija, 2021-11-05 [InstanceEdit:9758284] Orlic-Milacic, Marija, 2021-11-10 [InstanceEdit:9758460] Orlic-Milacic, Marija, 2021-11-12 [InstanceEdit:9764006] Orlic-Milacic, Marija, 2022-02-08 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08 name CDK6 inhibitors bind CDK6 output [DefinedSet:9754128] p-T177-CDK6:CCND:CDK6 inhibitors [nucleoplasm] [Homo sapiens] precedingEvent
releaseDate 2021-12-08 reviewed [InstanceEdit:9757975] Kadambat Nair, Sisira, 2021-11-02 reviewStatus [ReviewStatus:9821382] five stars species [Species:48887] Homo sapiens stableIdentifier [StableIdentifier:9754138] R-HSA-9754129.3 summation [Summation:9756552] The following small kinase inhibitors have been shown to com... (hasEvent) [Pathway:9754119] Drug-mediated inhibition of CDK4/CDK6 activity [Homo sapiens]
[Change default viewing format]
List...
Protein identifiers
ChEBI identifiers
KEGG COMPOUND identifiers
No pathways have been reviewed or authored by CDK6 inhibitors bind CDK6 (9754129)
